Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BXRX =MC $86 m a great buying opp after the drop
https://www.rttnews.com/3071353/baudax-bio-s-bxrx-non-opioid-pain-drug-makes-it-to-the-finish-line.aspx
ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing.
Baudax expects ANJESO to be available in the U.S. in late April or early May 2020.
Esther Hong, an analyst at Janney Montgomery, estimates peak sales of the drug in the U.S. to reach about $355 million.
Next is CTDH with imminent resoults of their Niemann-Pick Diesease a $500 Million Market with NO approved Drug to date
CTDH= Price 0.18 --MC $23 M --Clinical results from NPC trial imminent (during this Q) ,positive results could boost this unknown stock to $1 or more in no time .They have also an attractive Alzheimer programm ongoing . Dirt cheap stock with BRUTAL upside potential .GLTA
CTDH= MC $23 M --Clinical results from NPC trial imminent (during this Q) ,positive results could push this unknown stock to $1 or more in no time .They have also an attractive Alzeimer programm ongoing . Dirt cheap stock with BRUTAL upside potential .GL
Cyclo Therapeutics (CTDH)
Market Cap $23 M
Cash $5 M << Cash till end of the year
Price: 0.19
Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C
https://finance.yahoo.com/news/last-patient-last-visit-cyclo-131300434.html
Data cleaning underway, top line results expected the first quarter of 2020
Cyclo Therapeutics Receives Buy Recommendation and $1.25 Price Target from ThinkEquity
https://finance.yahoo.com/news/cyclo-therapeutics-receives-buy-recommendation-120000882.html
CTDH= MC $23 M --Clinical results from NPC trial imminent (during this Q) ,positive results could push this unknown stock to $1 or more in no time .They have also an attractive Alzeimer programm ongoing . Dirt cheap stock with BRUTAL upside potential .GL
Cyclo Therapeutics (CTDH)
Market Cap $23 M
Cash $5 M << Cash till end of the year
Price: 0.19
Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C
https://finance.yahoo.com/news/last-patient-last-visit-cyclo-131300434.html
Data cleaning underway, top line results expected the first quarter of 2020
Cyclo Therapeutics Receives Buy Recommendation and $1.25 Price Target from ThinkEquity
https://finance.yahoo.com/news/cyclo-therapeutics-receives-buy-recommendation-120000882.html
APPROOOOOOOOOOOOOOOOOOOOOOOVED
Next SOLAR gem aout to explode ..SOL is one of the cheapest solar gems out there ..this undiscovered low float could hit $5+ in no time on current hype in the sector
SOL = UP 13% ..could be a hot play for tomorrow ,,competitor ENPH which is valued at $7 billion is up 45% today ..
SOL = MC $75 M CHEAPEST Solar company , looks like the sector is about to explode and this stock is one of the cheapest in the area
XERS =MC $140 M - Cash $130 M -- FDA approved treatment for severe hypoglycemia will be launched next Q --3x Phase 2 readouts for different indications during 1H 2020 /Brutally underpriced and undiscovered stock with HUGE upside
https://www.fiercepharma.com/pharma/xeris-scores-first-fda-nod-shelf-stable-glucagon-injector
RBC Capital Markets analyst Randall Stanicky said the wait on the autoinjector was only a "modest surprise" and projected peak sales for Gvoke at $248 million per year in 2024.
ZSAN = FDA NEWS IMMINENT regarding NDA acceptance likely to hit the wire within 10 days
Market Capof around $20 million is a pure gift for a company which has 1 Drug awaiting FDA approval and another one close to Phase 3 readout ..GL
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYY NDA acceptance news within 10 days = back to $1.50 quickly
strong buy
ZSAN..UP 10% still time to get in cheap
market cap around $17 million after Offering --NDA acceptance news expected within next 10 days which likely to boost the stock higher ..
ZSAN =MC $16 M -- Migraine Drug close to FDA approval --Next Drug in final Phase 2/3 trial = Offering creates a MONSTER BUYING OPP....LOAD UP guys before she runs higher
strong buy ahead of NDA acceptance expected within days
ZSAN -Looks like Rebound starts which could drive the stock close or even above $1 ..Stock is terrible underpriced at around $18 million valuation (after Offering)
MAJOR REBOUND could start anytime now
ZSAN =MEGA BUYING OPP on Offering news
ZSAN= Market Cap around $15 M (after Offering) Cash $10 M -- 1 Drug awaiting FDA approval and another Drug is in final Phase 2/3
New Presentation
http://ir.zosanopharma.com/static-files/ed3b87fb-d51c-433f-ac81-bf701471e030
ZSAN =MEGA BUYING OPP on Offering news
ZSAN= Market Cap around $15 M (after Offering) Cash $10 M -- 1 Drug awaiting FDA approval and another Drug is in final Phase 2/3
New Presentation
http://ir.zosanopharma.com/static-files/ed3b87fb-d51c-433f-ac81-bf701471e030
ZSAN =MC $20 M --News regarding NDA acceptance could hit the wire any time now this could push ZSAN 30% higher and more.Great buying opp here close at ATL .GL
Zosano Announces FDA Submission of New Drug Application for Qtrypta...December 23, 2019
https://finance.yahoo.com/news/zosano-announces-fda-submission-drug-130010425.html
Presentation
http://ir.zosanopharma.com/static-files/5d165c8e-8ce8-4dde-9d5c-d0243f9bec1e
ZSAN ..NDA acceptance expected within 12 days , this could boost the stock thats why i got in today
ZSAN =MC $20 M --FDA Acceptance is coming within days this could push the low float stock quickly toward $2 . Stock is oversold and brutally underpriced at $20 million valuation .GL
Zosano Pharma (ZSAN)
Market Cap $20 Million
Cash $10 Million
Price: $1.14
Shares Out: 17,7 Million
Zosano Announces FDA Submission of New Drug Application for Qtrypta
https://finance.yahoo.com/news/zosano-announces-fda-submission-drug-130010425.html
Presentation
https://seekingalpha.com/article/4291850-zosano-pharma-zsan-investor-presentation-slideshow
IGXT =MCap $33 M--FDA DECISION for Migraine Oral-film on March 26 and Launch of Cannabis Products by partner Tilray also expected during this Quarter =500% UPSIDE POTENTIAL ..
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
STRONG Pipeline
IGXT =MCap $33 M--FDA DECISION for Migraine Oral-film on March 26 and Launch of Cannabis Products by partner Tilray also expected during this Quarter =500% UPSIDE POTENTIAL ..
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
STRONG Pipeline
(BXRX) FDA DECISION in 16 Days
BXRX =MC $80 M -Cash $20 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
(BXRX)FDA DECISION IN 16 DAYS
BXRX =MC $79 M -Cash $20 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
IGXT =Price 0.36 --MCap $34 M--FDA DECISION for Migraine Oral-film on March 26 and Launch of Cannabis Products by partner Tilray also expected during this Quarter = 500%+ UPSIDE POTENTIAL ..
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
BXRX =FDA DECISION on FEB.20
BXRX =MC $79 M -Cash $20 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
FDA DECISION ON FEB.20--- GREAT buying opp
BXRX =MC $79 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
FDA DECISION ON FEB.20 ...load up
CORONAVIRUS GEM ..underpriced low float stock
IGXT =MC $33M--FDA DECISION & LAUNCH OF CANNABIS Products partnered with Tilray bot milestones expected during THIS Quarter
IGXT =Price 0.36 -MC $33 M--FDA DECISION for Migraine drug on March 26 and Launch of Cannabis Products by partner Tilray expected during this Quarter !!!! Stock could run to $2 ahead of the FDA decision in March .GL
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
IGXT =MC $33M--FDA DECISION & LAUNCH OF CANNABIS Products partnered with Tilray bot milestones expected during THIS Quarter
IGXT =Price 0.36 -MC $33 M--FDA DECISION for Migraine drug on March 26 and Launch of Cannabis Products by partner Tilray expected during this Quarter !!!! Stock could run to $2 ahead of the FDA decision in March .GL
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020